Table 2.
Event | No Event | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Reference | Year | Study Design | Follow-up (months) | Population of interest | N | PAI-1 Activity (U/mL) | Range | Death | MI | Restenosis | N | PAI-1 Activity (U/mL) | Range |
Sane et al. [50] | 1991 | Cohort | 24 | Fibrinolytics | 28 | 17 | 16 | n/a | n/a | 28 | 328 | 19 | 21 |
Shah et al. [72] | 1992 | Cohort | 9 | Elective PCI | 28 | 8 | 7.1 | n/a | n/a | 28 | 40 | 12 | 8 |
Gray et al. [73] | 1993 | Cohort | 0.1 | MI | 13 | 20.6 | 11 | n/a | 13 | n/a | 85 | 20.1 | 7.9 |
Malmberg et al. [74] | 1994 | Case-Control | 90 | MI | 53 | 23.75 | 13.34 | 20 | 33 | n/a | 55 | 18 | 10.97 |
Brack et al. [75] | 1994 | Cohort | 4 | Elective PCI | 16 | 4.63 | 4.71 | n/a | n/a | 16 | 30 | 5.77 | 5.06 |
Nordt et al. [54] | 1998 | Cohort | 12 | Fibrinolytics | 5 | 8.7 | 8.3 | n/a | 5 | n/a | 26 | 9.9 | 8.2 |
Jansson et al. [76] | 1998 | Cohort | 120 | MI | 54 | 9.1 | 5.1 | 54 | n/a | n/a | 69 | 10.6 | 7.1 |
Wiman et al. [77] | 2000 | Case-Control | 3 | MI | 61 | 22.1 | 17.5 | n/a | 61 | n/a | 95 | 18.2 | 16.5 |
Wiman et al. [77] | 2000 | Case-Control | 3 | Ml | 25 | 15.4 | 13.6 | n/a | 25 | n/a | 38 | 17.8 | 12.4 |
Prisco et al. [78] | 2001 | Cohort | 18 | MI | 18 | 11.27 | 7.64 | n/a | n/a | 18 | 36 | 15.8 | 27.49 |
Prisco et al. [78] | 2001 | Cohort | 18 | Elective PCI | 6 | 8.33 | 8.1 | n/a | n/a | 6 | 42 | 7.57 | 9.52 |
Sargento et al. [79] | 2003 | Cohort | 12 | MI | 7 | 6.34 | 1.56 | 5 | 2 | n/a | 80 | 4.47 | 1.84 |
Marcucci et al. [19] | 2006 | Case-Control | 22 2 | MI | 109 | 22 | 9.09 | 54 | 55 | n/a | 411 | 24.25 | 10.63 |
Schoebel et al. [80] | 2008 | Cohort | 2 | MI | 18 | 3.7 | 1.8 | n/a | n/a | 18 | 42 | 5.3 | 3.2 |
Wiman et al. [77] is presented twice as data for men and women were reported separately